eurasanté
Invest for Success

NORTHERN FRANCE
HEALTH AND NUTRITION
CENTRE OF EXCELLENCE

Tel. +33 (0)3 28 55 90 60 | **email:** contact@eurasante.com | **Website:** www.eurasante.com

EURASANTÉ AGENCY:

A LEADING EUROPEAN HEALTHCARE CLUSTER

eurasanté
Entreprendre et Réussir

Since 1994, Eurasanté has strived to develop the nutrition and health sectors in the Hauts-de-France region.

1994

Creation of Eurasanté association at the Lille University Hospital's initiative

1996

Creation of **Eurasanté Bio-Business Park, hosting for biotechs and pharma ex. Bayer**

1999

Labelling of the **Eurasanté Bio Incubator** by the Ministry of Higher Education, Research, and Innovation

2005

Creation of the **BioFIT** business convention**.**

2010

Labelling of Clubster NSL as business cluster.

2014

Creation of the 'Invest'Innove' investment platform

2017

The Eurasanté Bio Incubator **is ranked among the top 15 European biotech incubators for the emergence of innovative start-ups** (Labiotech.eu)

2021

First closing of our investment vehicule **Captech Santé at 15 million euros**

EURASANTE BIO-INCUBATOR AND BIO-ACCELERATOR

EMERGENCE OF INNOVATIVE HEALTHCARE COMPANIES

300+ projects supported

Biotech / Medtech / Digital Health

170 COMPANIES created

€670 M
Equity raised

1,300 JOBS
created

30% projects
come from
academic research

OUR PROGRAMMES

eurasanté
Invest for Success

BIO-INCUBATOR | **BIO-ACCELERATOR**

4 committees/year to evaluate new projects

Bio-Start

De-risk the project
Construction of an initial business plan

Bio-Incubation

Launch & implement
Up to the first fund raising

Bio-Acceleration

Structure & Develop
Up to Series A fund raising



STRATEGIC DEVELOPMENT

SEARCH FOR FUNDING

HR/TRAINING

COMMERCIAL DEVELOPMENT

LAWS AND REGULATIONS



COMMUNICATION AND MARKETING

3 PROMISING BIOTECHS

CURRENTLY IN INCUBATION

eurasanté
Entreprendre et Réussir

NanoReviv

Reviving Antibiotics

Fighting antibioresistance

The context: Anti-Microbial Resistance

- Start up founded by Dr Amokrane Regal, Microbiologist, in 2023
- Targeting Antimicrobial resistance: Urgent global public health threat, killing at least 1.27 million people worldwide/ year - Estimated 10 M / year by 2050 (1)
- Osteo-Articular Infections (2, 3)
  - Causative bacteria: resistant Staphylococcus
  - WHO bacterial priority pathogen list
  - Surgery + prolonged intravenous antibiotics
  - Failures: 20-30% (resistant bacteria, weakly penetration of antibiotics)



(1) https://www.who.int/news; (2) Lubbeke A et al (2018) J Health Policy, 122(5), 548-557; (3) Benjamin D. B. PLOS One March 2017

Technology & product

- Development of a thermosetting gel containing lipid nanocapsules.
- **Nanocapsules contain Daptomycin** (generic antibiotic), used notably to treat osteoarticular infections.



- **First product: Staph-EX,** a ready to use syringe containing the gel
  - Applied once and locally during the osteoarticular surgery
  - To cure or prevent OAI
  - **Targeting the bacteria directly on the infection site**
  - **Preclinical POC established**



✓ 1 injection: More effective than 14 IV injections of daptomycin

✓ Completely eradicates bacteria

✓ No variant resistant detected

NanoReviv
Reviving Antibiotics

Challenges encountered by NanoReviv

- Lack of clarity regarding the preclinical / clinical plan milestones to set up: guidelines/roadmap would be appreciated regarding the protocol, nb of patients to include, doses etc.

- Lack of guidance in the SMEs answers to start ups: rather than a non compliant/compliant type of answer, advice or guidance regarding the actions to implement would be highly appreciated

Genvade Therapeutics

Develop targeted medicines for genetic diseases of nonsense mutations

Context : Rare Disease & Nonsense Mutations

- Start-up founded in 2021 by Dr Fabrice Lejeune, Researcher at INSERM

- 7000 rare diseases, including 80 % with a genetic origin
  - ➢ **10 % with a nonsense mutation**

- Nonsense mutation caused some of the most devastating diseases including *Cystic Fibrosis, Duchenne Muscular Dystrophy, etc.*

Mission :

- Create a pipeline of therapeutic products to treat genetic diseases by targeting the mutations at the origin of the pathology

Technology & Product

Lead Product : GV-01

- Small molecule drug candidate to correct/ readthrough UGA nonsense mutations.
- First pathology / indication : **Cystic Fibrosis (multi-organ disease)**
    - 10-12% of patients carry a nonsense mutation, 50% of them carrying a UGA nonsense mutation

Preclinical POC established :

- POC on CF patient cells (high efficacy / no toxicity)
- POC on organoids derived from patient cells
- POC on animal model carrying a nonsense mutation

Challenges encountered by Genvade

Lack of clarity regarding the ODD process :

- At which development steps shall the start-up start the process?
- What type of data is needed?
- When will the new criteria be applicable ?
- Shall the start-up wait for them to be established to apply?
- Who to contact if the start-up has questions?

InVenis Biotherapies

A new hope for neurodegenerative diseases and acute neurotraumatic disorders

Context : neurodegenerative diseases

Spin-off from the University of Lille and Taipei Medical University, created in 2021

Mission :

- Leveraging the tissue healing and repair functions of blood platelets by integrating it into innovative therapies to treat neurodegenerative pathologies.

1st indication : **Amyotrophic Lateral Sclerosis (ALS)**

- The most rapidly fatal neurodegenerative disease, leading to death within 3-5 years after diagnosis.
- On global scale, 250 000 ALS patients

InVenis Biotherapies

Technology & Product

First Product :

- **GIFT-FULL** : Obtained by production of several Heated Platelet Pellet Lysate (HPPL).
- Treat neurodegenerative diseases by improving neuroprotection and neurorestauration, i.e. the protection of the central nervous system.
- Currently in pre-clinical developement

Benefits :

- **Efficacy** : Overcome the challenge of the blood-brain barrier with an implantable Intracerebroventricular (ICV) delivery system.
- **Safety** : No adverse effects of the ICV delivery system observed in previous clinical trial on 12 Parkinson patients.

InVenis Biotherapies

Challenge encountered by Invenis Biotherapies

<u>Lack of internal expertise to request a EMA scientific advice:</u> the start up is still early stage and is not capable to fill on its own a robust file that would enable the most relevant answers from EMA experts. The need to hire external experts to draft the file is financially challenging.